Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?

Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.

Barchart

Cost of Mounjaro to be discounted in UK pharmacies

It comes after an announcement from Eli Lilly that the UK list price for the drug is set to rise from September 1.

Evening Standard

Eli Lilly to offer UK discount on Mounjaro weight-loss jabs

IN FULL

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Mounjaro weight-loss jab ‘to be offered at discounted prices to pharmacies’

Cost of drug still set to more than double after Donald Trump told manufacturers to raise charges outside US

The Independent UK

Stock Of The Day: Another Breakout For Eli Lilly?

Trading is quiet in Eli Lilly and Co (NYSE:LLY) on Thursday. The stock has stalled out at a resistance level.

Benzinga

Warning over Mounjaro ‘golden dose’ as users panic over shortages and soaring prices

With the price of Mounjaro to rise in September, some users are using leftover medication in syringes to create an extra dose

The Independent UK

UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears

Patients across the United Kingdom are struggling to obtain the weight-loss and diabetes drug Mounjaro as demand surges ahead of a sharp price increase set for September.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Mounjaro maker pauses shipments of weight loss drug to UK

US firm Eli Lilly reportedly tells British wholesalers to stop taking orders as demand soars before September price rise

The Guardian - UK

Why Mounjaro sales to UK wholesalers have been suspended

IN FULL

The Independent UK

Mounjaro weight loss jab sales are halted in the UK as drugmaker looks to beat price rise

Eli Lilly, the manufacturer of Mounjaro, has temporarily suspended deliveries of the drug to UK pharmacies in response to ‘unprecedented demand’

Evening Standard

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Sales of Mounjaro weight loss jab to UK suspended as pharmacies hit by shortage ahead of price hike

Boots and Lloyds pharmacies among those running low after users stockpile drug ahead of price hike

The Independent UK

New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate significant progress in survival outcomes for high-risk early breast cancer patients.

Benzinga

‘I lost more than 2 stone on Mounjaro - but my hair started to fall out’

Rhiannon Anne Griffiths-Bowen says the weight-loss benefits of taking Mounjaro outweighed the issue of hair loss

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Stock Jumps On Weight-Loss Pill Trial

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.

MarketBeat

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

The Independent UK

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

Benzinga

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Eli Lilly’s once-daily weight loss pill succeeds in latest trial, paving the way for global approval

Lilly said it plans to ask regulators to approve the drug by the end of 2025.

The Guardian - UK

‘Gutted’: UK users of weight loss jab Mounjaro devastated by planned price hike

People using the jab reported positive results, but many say the increased cost will be prohibitively expensive, and they expect to put the weight back on when they stop

The Guardian - UK

Mounjaro users in UK warned against bulk buying before autumn price rise

Cost may increase as much as 170% from September, but patients warned against a quick switch to Wegovy

International Business Times UK

UK Sales of Wegovy Skyrocket 2,000% as Dieters Dump Mounjaro After 170% Price Hike

This trend drove WeGovy sales to jump 27 times higher — a 2,660% increase — on Wednesday compared with the typical daily average last month.

Barchart

The Saturday Spread: 3 Beaten-Down Stocks That Are Potentially Poised for a Recovery (V, LLY, ABNB)

Although the market has been uncomfortably choppy in recent sessions, this is also the time for contrarians to pick up hot securities on the cheap.

Benzinga

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Euronews

Serena Williams reveals GLP-1 treatment helped her lose 31 pounds after giving birth

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.